uniQure Announces to Present at Multiple Conferences in May

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 27, 2018 -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical and scientific conferences in May.

• 2^nd Annual Gene Therapy Day for Rare Disorders, April 30 – May 2, 2018 at the Sheraton Boston Hotel, Boston, MA.
  
      o Steven Zelenkofske, D.O., chief medical officer at uniQure, will be presenting “Evolving a Strategy to Narrow Down the Potential Scope of Development in the Gene Therapy Space” on Tuesday, May 1^st at 9:30 a.m. ET
   
• American Society of Gene and Cell Therapy (ASGCT) Commercialization Workshop, May 15, 2018 at the Hilton in Chicago, IL.
  
      o Jonathan Garen, chief business officer at uniQure, will be participating in the Industry Perspectives Panel, on Tuesday, May 15^th at 4:15 p.m. CT.
   
• World Advanced Therapies & Regenerative Congress 2018, May 16 – May 18, 2018 at the Business Design Centre in London, United Kingdom. 
  
      o Paul Firuta, chief commercial officer at uniQure, will be participating in a panel discussion: “Pricing, Reimbursement, and Market Access for Cell & Gene Therapies: Challenges and Potential Solutions” on Wednesday May 16^th at 2:50 p.m. GMT.
   
• The 21^st Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT), May 16 – 19, 2018 at the Hilton in Chicago, IL.
  
      o Multiple presentations have been accepted for presentation at the 21^st Annual Meeting of the ASGCT.  Further details will be forthcoming at time of abstract publications. 
   
• Synpromics Scientific Symposium, May 16, 2018 at the 21^st ASGCT Annual Meeting, in Chicago, IL.
  
      o Francois du Plessis, senior scientist vector development, will be presenting on the development of next generation synthetic promotors for liver directed gene therapy, at Wednesday, May 16^th at 6:00 p.m. CT.
   
• World Federation of Hemophilia (WFH) 2018 World Congress, May 20 – 24, 2018 at the Scottish Event Campus (SEC), in Glasgow, Scotland.
  
      o Data on surgery and bleed management from the AMT-060 study in hemophilia B patients will be presented in an oral presentation: “Surgery and Bleed Management in Patients Receiving AMT-060 in a Phase I/II trial: Evaluation of the Safety of Exogenous FIX Treatment after Gene Transfer” by Prof. W. Miesbach M.D., Ph.D., investigator of the trial, in an oral presentation on Tuesday, May 22^nd at 10:15 a.m. GMT.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com

uniQure Contacts

For Investors:                                                                                                      

Maria E. Cantor                                                                             
Direct: 339-970-7536                                                          
Mobile: 617-680-9452                                                       
[email protected]                                                 

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
[email protected]

For Media:

Tom Malone
Direct:  339-970-7558
Mobile:  339-223-8541
[email protected]